

February 29, 2012



## Pressure BioSciences, Inc. to Discuss Fourth Quarter and FY2011 Financial Results and Provide Business Update

SOUTH EASTON, Mass., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) today announced that the Company will host a teleconference to discuss its Q4 and FY2011 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone or through a live web-cast. The teleconference and web-cast information is provided below:

Date: Wednesday, February 29, 2012

Time: 4:30 p.m. Eastern Standard Time (EST)

To attend this teleconference via web-cast, please visit the Company's website:

[www.pressurebiosciences.com](http://www.pressurebiosciences.com)

To attend this teleconference via telephone:

Dial-in number: (888) 383-9147

For those unable to participate in the live teleconference, a replay will be accessible through the Company's website approximately one hour after the call ends through March 29, 2012.

### About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (Nasdaq:PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated \$6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

#### CONTACT: Investor Contacts:

Richard T. Schumacher, President & CEO  
Joseph Damasio, Jr., VP of Finance & Admin  
Pressure BioSciences, Inc.  
(T) 508-230-1828

Source: Pressure BioSciences, Inc.